Navigation Links
Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer

those cells. The FUS1 nanoparticle formulation was developed and tested in Roth's lab. It advanced to phase I clinical trial after a promising test on human non-small cell lung cancer in a mouse model.

FUS1 was discovered by a research team led by Roth at M. D. Anderson and by John Minna, M.D., of the Department of Internal Medicine and Pharmacology, Hamon Center for Therapeutic Oncology Research, at The University of Texas Southwestern Medical Center at Dallas. Roth and Minna are the co-principal investigators of a National Cancer Institute Specialized Program of Research Excellence in Lung Cancer.

"As a clinician, I am very cautious about saying that we have shown clinical activity at this point. We have some encouraging data. The number of patients is too small to draw any definite conclusions, however," Lu said.

Three patients of eight who received two or more doses experienced stable disease for three to seven months. Median survival time for all patients is 14.6 months, which Lu notes compares favorably to a seven-month median survival time for patients receiving second line therapy.

All patients on the trial had been treated with front line cisplatin combination chemotherapy, which failed to halt their disease. The clinical trial continues. No maximum tolerated dose has been established, Lu says.

The nanoparticle delivery system consists of a plasmid gene expression cassette loaded with DNA that encodes the FUS1 protein. This is wrapped tightly in a form of cholesterol to protect it from the body's defense mechanisms. The nanoparticles accumulate mainly in the lungs, particularly in the tumors, where the genes repeatedly express FUS1 tumor-suppressing proteins.

Lung cancer is the leading cause of cancer death in the United States, causing 160,000 deaths annually. About 80 percent of lung cancer is of the non-small cell type.


'"/>

Source:University of Texas M. D. Anderson Cancer Center


Page: 1 2

Related biology news :

1. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
2. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
3. Probing the promise and perils of nanoparticles
4. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
5. Using nanoparticles, in vivo gene therapy activates brain stem cells
6. NJIT study shows nanoparticles could damage plant life
7. Jefferson researchers find nanoparticle shows promise in reducing radiation side effects
8. Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates
9. Gold nanoparticles could improve antisense cancer drugs
10. MIT nanoparticles may help detect, treat tumors
11. Quantum dots reviewed -- Could these nanoparticles hold the cure to cancer?
Post Your Comments:
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ... new funding to expand its team and bring LaunchKey ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... you are overweight and pregnant, your baby isn,t destined to ... research report published online in The FASEB Journal ... show that modifying fat intake during pregnancy to a moderate ... mother,s size. Specifically, they found that a protein called "SIRT1" ...
... This release is available in Spanish . ... United States as a source of sugar for syrup and ... make it uniquely suited to production as a bioenergy crop, ... an ideal candidate because of its drought tolerance, adaptability to ...
... industry are excellent sources of proteins and healthy oils ... moment these side streams are mainly used as fish ... waste. Coordinated by VTT, the APROPOS (Added value ... project seeks to enrich several co-stream components at once ...
Cached Biology News:Eating well during pregnancy reduces baby's obesity risk regardless of mom's size 2Sorghum eyed as a southern bioenergy crop 2Food industry's high-quality co-streams used effectively as raw material for new products 2
(Date:12/24/2014)... Dec. 24, 2014   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade hypothermic storage ... precision thermal shipping products for cells and tissues  ... hold its 2015 Annual Meeting of Stockholders on May ... expected date for the Annual Meeting represents a change ...
(Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
(Date:12/24/2014)... December 23, 2014 Pipette.com announces their ... Twitter followers can submit their #HolidayInTheLab pictures for a ... lab mates. , For those struggling to think of ... Pipette.com Holiday in the Lab Contest provides the ideal ... followers to send pictures of their chemistree, holiday ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Wis. - Its not news that Wisconsin trails national ... whys of it are broken down and detailed in ... Venture Capital published by NorthStar Economics, Inc. The ... capital for Wisconsin companies. , ,The Wisconsin Technology Network ...
... Bays Nsight Telservices (www.nsighttel.com) in 2001 as Vice President ... as Chief Technical Officer (CTO) of Chicago startup BidBuyBuild. ... NET Cable, and NetNet and heads up the company's ... deployment. , , WTN: How did your dot-com ...
... more difficult challenges in business is turning around a sick ... the company is forced into bankruptcy. Realizing the painful reality ... impossible for owners and senior executives to deal with truthfully. ... them, and they will close that big outstanding proposal, and ...
Cached Biology Technology:Growing Venture Capital in Wisconsin 2Growing Venture Capital in Wisconsin 3Interview: WTN Gets Real with Appletons Brad Hansen - Dot-Com Experience helps Executive to Spot Trends 2Interview: WTN Gets Real with Appletons Brad Hansen - Dot-Com Experience helps Executive to Spot Trends 3Turning Around a Sick Company 2
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Biology Products: